Investigational New Drugs
IF
3.85
Papers
3,206
Papers 3,431
1 page of 344 pages (3,431 results)
Newest
#1Hisanaga NomuraH-Index: 3
#2Daiki Tsuji (University of Shizuoka)H-Index: 12
Last. Toshikatsu KawasakiH-Index: 1
view all 10 authors...
PURPOSE Docetaxel, cisplatin, and 5-fluorouracil (DCF) have high response rates, but severe neutropenia is frequently observed. The occurrence of neutropenia is associated with high histological response in solid tumors, and it might be associated with tumor shrinkage after DCF therapy. This study aimed to determine the genetic polymorphisms involved in the clinical response to preoperative DCF therapy in esophageal cancer patients. METHODS We included 56 patients with measurable lesions who rec...
Source
#1Ari NishimuraH-Index: 1
#2Akira OnoH-Index: 33
Last. Toshiaki TakahashiH-Index: 47
view all 17 authors...
Source
#1Thomas Yau (HKU: University of Hong Kong)H-Index: 49
#2Paul N. M. ChengH-Index: 6
Last. Chi Tao Ng (HKU: University of Hong Kong)
view all 8 authors...
Introduction. We investigated the safety and efficacy of a pegylated arginase (PEG-BCT-100) in combination with chemotherapy (oxaliplatin and capecitabine) [PACOX] in advanced HCC patients. Methods. This was a single centre phase 1 trial to assess the safety and tolerability of PACOX. All the enrolled subjects received treatment in 3-weekly cycles: intravenous PEG-BCT-100 2.7 mg/kg on days 1, 8 and 15 of each cycle; oral capecitabine 1000 mg/m2 twice daily on day 1–14 of each cycle and intraveno...
Source
#1Xiaowei Zhang (Fudan University)H-Index: 13
Last. Zhiguo Luo (Fudan University)H-Index: 4
view all 12 authors...
Background null Mucosal melanoma is rare and has distinct clinical and genetic features. Even with advances in targeted and immune therapies, the survival of patients with advanced or recurrent mucosal melanomas remains poor. The standard treatment remains controversial and we conducted this real-world study aimed to explore continuous intravenous recombinant human endostatin (Rh-endostatin) infusion plus chemotherapy in this population in the first-line setting. null Methods null Overall, 43 pa...
Source
#1Meijuan Huang (Sichuan University)H-Index: 23
#2Yongmei Liu (Sichuan University)H-Index: 12
Last. You Lu (Sichuan University)H-Index: 43
view all 8 authors...
Background. Anlotinib hydrochloride is an oral small molecule inhibitor of multiple tyrosine kinases, and it has been approved as a third-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) in China. This dose-exploration study was designed to investigate the feasibility of anlotinib in combination with other chemotherapy regimens in patients with nonsquamous NSCLC. Methods. This phase I study followed a 3 + 3 dose reduction design with three doses of anlotinib (12 mg, 10 ...
Source
#1Kosei Doshita (YCU: Yokohama City University)
#2Hirotsugu KenmotsuH-Index: 27
Last. Toshiaki TakahashiH-Index: 47
view all 21 authors...
Introduction: In patients with limited disease small cell lung cancer (LD-SCLC) treated with concurrent chemoradiotherapy (CCRT), long-term survival data have not been fully evaluated. Moreover, the association between long-term prognosis and prognostic factors has not been sufficiently investigated. Methods: In this retrospective study, we evaluated the efficacy of CCRT in 120 patients with LD-SCLC with a plan for curative CRT using concurrent accelerated hyperfractionated radiotherapy. Results...
Source
#1Nadire Özenver (Hacettepe University)H-Index: 5
#2Sara Abdelfatah (University of Mainz)H-Index: 10
Last. Thomas Efferth (University of Mainz)H-Index: 95
view all 5 authors...
Multiple myeloma (MM) is a devastating disease with low survival rates worldwide. The mean lifetime of patients may be extendable with new drug alternatives. Aurora A kinase (AURKA) is crucial in oncogenesis, because its overexpression or amplification may incline the development of various types of cancer, including MM. Therefore, inhibitors of AURKA are innovative and promising targets. Natural compounds always represented a valuable resource for anticancer drug development. In the present stu...
Source
#1Chie Ishikawa (University of the Ryukyus)H-Index: 21
#2Naoki Mori (University of the Ryukyus)H-Index: 55
Human T cell leukemia virus type 1 (HTLV-1) is responsible for adult T cell leukemia (ATL); however, molecular and cellular mechanisms underlying HTLV-1-induced leukemogenesis are unclear. BCL6 oncogene is involved in cancer progression and a preferred target of anti-cancer treatments. Here, we aimed to evaluate BCL6 expression and the effects of BCL6 inhibitor (FX1) on HTLV-1-infected T cell lines. BCL6 expression was higher in HTLV-1-infected T cell lines than that in uninfected T cell lines. ...
Source
#1Ari NishimuraH-Index: 1
#2Akira OnoH-Index: 33
Last. Toshiaki TakahashiH-Index: 47
view all 17 authors...
Background. Prognostic data on Japanese patients receiving durvalumab after chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC) are insufficient. Whether pneumonitis has prognostic implications in patients with LA-NSCLC who have received durvalumab also remains unclear. Methods. We retrospectively assessed the data of 82 consecutive patients who had received durvalumab after CRT at our institution between May 2018 and August 2020. A multi-state model was used to es...
Source
#1Xia Yuan (CSU: Central South University)
#2Yi He (CSU: Central South University)
Last. Wei Wang (CSU: Central South University)
view all 4 authors...
Background. Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer. According to reports, leukotriene B4 receptor 2 (LTB4R2, also known as BLT2), a chemokine receptor, is upregulated in different tumors. However, the correlation between BLT2 expression and its prognostic value in ccRCC remains to be explored. Methods. This study used the The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases to evaluate the association between BLT2 expression and the clinical...
Source
12345678910
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.